Janssen’s warm autoimmune hemolytic anemia therapy Imaavy (daratumumab?—not specified in the provided text) secured a Japan label expansion, marking the first approval specifically for warm autoimmune hemolytic anemia in the market described. The update adds an additional population for clinicians treating the rare autoantibody-driven disease, where severe anemia and fatigue can be difficult to manage. The label change underscores continued regulatory momentum for monoclonal antibody programs in immune-mediated hematology, including incremental indications that broaden real-world use beyond initial approvals. Japanese approvals also highlight how post-approval evidence packages can reshape commercial positioning on a country-by-country basis.